Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

Af­ter a “hot” pe­ri­od of rapid growth be­tween 2009 and 2012, and a rel­a­tive­ly “cool­er” pe­ri­od of slow­er growth from 2013 to 2015, Chi­na has once again be­come a top-of-mind pri­or­i­ty for the CEOs of most large, multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies.

At the In­ter­na­tion­al Phar­ma Fo­rum, host­ed in March in Bei­jing by the R&D Based Phar­ma­ceu­ti­cal As­so­ci­a­tion Com­mit­tee (RD­PAC) and the Phar­ma­ceu­ti­cal Re­search and Man­u­fac­tur­ers of Amer­i­ca (PhRMA), no few­er than sev­en CEOs of ma­jor multi­na­tion­al phar­ma­ceu­ti­cal firms par­tic­i­pat­ed, in­clud­ing GSK, Eli Lil­ly, LEO Phar­ma, Mer­ck KGaA, Pfiz­er, Sanofi and UCB. A few days ear­li­er, the CEOs of sev­er­al oth­er large multi­na­tion­als at­tend­ed the Chi­na De­vel­op­ment Fo­rum, an an­nu­al busi­ness fo­rum host­ed by the re­search arm of Chi­na’s State Coun­cil. It’s hard to imag­ine any oth­er coun­try, ex­cept the US, hav­ing such draw­ing pow­er at CEO lev­el.

What’s be­hind this trend? And more im­por­tant­ly, what are the im­pli­ca­tions?

I see four pri­ma­ry sources of val­ue cre­ation, ap­plic­a­ble across in­dus­tries for multi­na­tion­als op­er­at­ing in Chi­na, and nine main im­pli­ca­tions for phar­ma multi­na­tion­als to pon­der and de­bate.

1. Growth from mil­lions to bil­lions: Chi­na is al­ready a key con­trib­u­tor to the rev­enues and growth of multi­na­tion­al phar­ma com­pa­nies

This trend is not unique to the phar­ma­ceu­ti­cal sec­tor and can al­so be ob­served in medtech as well as the con­sumer and au­to sec­tors. For ex­am­ple, by 2030 Chi­na’s con­tri­bu­tion to glob­al growth in per­son­al con­sump­tion is ex­pect­ed to be equal to that of the US and West­ern Eu­rope com­bined. It is al­ready the largest mar­ket for sev­er­al im­por­tant prod­uct cat­e­gories, rang­ing from lux­u­ry goods to cars.

The trend is made clear in the quar­ter­ly earn­ings re­leas­es of most ma­jor phar­ma­ceu­ti­cal multi­na­tion­als. Their per­for­mance in Chi­na is of­ten a bright spot, and one they in­creas­ing­ly show­case. Some com­pa­nies even po­si­tion Chi­na as a “key pil­lar of fu­ture growth.”

For some, Chi­na is al­ready a top two con­trib­u­tor to to­tal top-line rev­enues, sec­ond on­ly to the US, while for oth­ers, it is the main growth dri­ver. At the end of the sec­ond quar­ter this year, sev­er­al com­pa­nies dis­closed year-to-date Chi­na growth fig­ures well above 30%. Giv­en the scale of busi­ness­es op­er­at­ing in Chi­na to­day—sev­er­al of which have rev­enues in the USD bil­lions—these num­bers have a mean­ing­ful im­pact on glob­al per­for­mance. For some com­pa­nies, Chi­na ac­counts for as much as 25% of glob­al growth.

2. In­no­va­tion: Chi­na is an emerg­ing source of prod­uct, port­fo­lio, and busi­ness mod­el in­no­va­tion

In a re­cent in­ter­view with Chi­na Dai­ly, No­var­tis’ head of glob­al drug de­vel­op­ment and chief med­ical of­fi­cer an­nounced that the com­pa­ny is work­ing on “hav­ing every piv­otal drug de­vel­op­ment pro­gram in­clude Chi­na from the be­gin­ning by de­fault.” Many com­pa­nies are em­bark­ing on that jour­ney, made pos­si­ble by the Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion (NM­PA) re­form.

Be­yond pipeline man­age­ment and ac­cel­er­a­tion, com­pa­nies are al­so tap­ping in­to Chi­na’s in­no­va­tion ecosys­tem. In the last three years we have seen As­traZeneca open a Com­mer­cial In­no­va­tion Cen­ter in Wuxi, Sanofi open a glob­al re­search in­sti­tute in Suzhou, Mer­ck KGaA open In­no­va­tion Hubs in sev­er­al lo­ca­tions, J&J in­tro­duce its JLAB con­cept in Shang­hai, No­vo Nordisk open its IN­NO­VO cen­ter in Bei­jing, and Roche an­nounce a new ear­ly re­search cen­ter in Shang­hai. While they may vary in scope and op­er­at­ing mod­els, all these cen­ters typ­i­cal­ly aim at fos­ter­ing in­no­va­tion through part­ner­ships with oth­er play­ers in the ecosys­tem.

3. Glob­al sup­ply chain: Chi­na emerg­ing in a more cen­tral role for bio­phar­ma

Sec­tors such as ad­vanced elec­tron­ics are like­ly to give Chi­na a cen­tral role in their glob­al sup­ply chain. For the bio­phar­ma sec­tor, how­ev­er, the trend is on­ly emerg­ing. While we do see sig­nif­i­cant man­u­fac­tur­ing ca­pac­i­ty for small mol­e­cule or­gan­ic com­pounds in main­land Chi­na—for both the Chi­nese mar­ket and for ex­port—multi­na­tion­al com­pa­nies have so far re­sist­ed adding ca­pac­i­ty for large mol­e­cule man­u­fac­tur­ing. This can be ex­plained by sev­er­al fac­tors, but most no­tably a con­cern around IP pro­tec­tion. One would ex­pect that, over time, this will be­come in­creas­ing­ly man­age­able. Al­ready, we ob­serve that some com­pa­nies, such as Boehringer In­gel­heim, op­er­ate plants for large mol­e­cule con­tract man­u­fac­tur­ing in main­land Chi­na, while oth­ers, like Lon­za, have an­nounced plans to do so.

4. Cap­i­tal and tal­ent: Chi­na’s role ex­pand­ing as a source of both

We have seen this trend play out clear­ly in the world of biotech, with Chi­nese VCs be­ing very ac­tive play­ers in glob­al fund­ing. In fact, in 2018, rough­ly 40% of biotech fund­ing in the US came from Chi­nese sources. We al­so see Chi­na phar­ma­cos and in­vestors—in­clud­ing Luye Phar­ma and Fo­s­un—mak­ing larg­er and larg­er strate­gic in­vest­ments out­side of Chi­na, how­ev­er it is still an ear­ly trend. On the tal­ent side, sev­er­al se­nior ex­ec­u­tives of lead­ing phar­ma com­pa­nies are Chi­na-based. For ex­am­ple, the cur­rent EVP of In­ter­na­tion­al for As­traZeneca and the head of the AP­MA re­gion for No­var­tis are both of Chi­nese ori­gin and based in Shang­hai.

So what does it all mean? Here are a few im­pli­ca­tions, and pre­dic­tions…

Up and up: Chi­na’s im­por­tance in many phar­ma com­pa­nies’ glob­al agen­das will con­tin­ue to rise, with an in­creas­ing num­ber of com­pa­nies man­ag­ing Chi­na as a re­gion, rather than as a coun­try with­in Asia-Pa­cif­ic. This is not to say that the cur­rent mod­el won’t con­tin­ue to work well, but as Chi­na grows big­ger as a coun­try, its ap­petite for in­vest­ment and im­pact on re­gion­al per­for­mance be­comes such that the APAC re­gion will in­creas­ing­ly re­sem­ble a Chi­na+ re­gion. As a re­sult, many com­pa­nies may de­cide to have Chi­na re­port more di­rect­ly to the CEO or to a di­rect re­port to the CEO.

Be­ware of the spot­light: The top-line con­tri­bu­tion of Chi­na to rev­enues and growth will be­come a hot top­ic, giv­en the vis­i­bil­i­ty of these met­rics to glob­al in­vestors. We are reach­ing the point at which per­for­mance in Chi­na can “move a stock.” The chal­lenge, how­ev­er, is pre­dict­ing Chi­na’s fu­ture growth with ac­cu­ra­cy—it re­mains at best a “guessti­mate.” Com­pa­nies will need to man­age ex­pec­ta­tions but could still find them­selves sur­prised by their per­for­mance on a quar­ter by quar­ter ba­sis.

Ex­pect peer pres­sure: As more and more com­pa­nies com­mu­ni­cate to in­vestors about their Chi­na per­for­mance and strat­e­gy, more dis­creet com­pa­nies could be asked by fi­nan­cial an­a­lysts to clar­i­fy their strate­gic stance to­wards the mar­ket. This is not to say that all com­pa­nies should nec­es­sar­i­ly make Chi­na a top pri­or­i­ty. But not do­ing so may in­creas­ing­ly re­quire a clear ex­pla­na­tion.

Be wary of ten­sions emerg­ing with pro­po­nents of the sta­tus quo: As Chi­na takes its right­ful po­si­tion at the glob­al board­room ta­ble, in­ter­nal ten­sions with tra­di­tion­al de­vel­oped mar­kets could in­crease. The rise of Chi­na as a glob­al pri­or­i­ty will in­evitably lead to some soul search­ing in mar­kets where growth prospects are more un­cer­tain or even de­clin­ing. Com­mit­ting to Chi­na re­quires more al­lo­ca­tion of re­sources—par­tic­u­lar­ly cap­i­tal and tal­ent—and will in­evitably lead to dif­fi­cult bud­getary dis­cus­sions as com­pa­nies aim to max­i­mize ROI on a glob­al ba­sis.

Mind the gap in sup­ply chain: De­mand in Chi­na is on a scale not seen else­where in the world. In the last few years, we have wit­nessed some sup­ply chain dis­rup­tion due to the sud­den up­take of de­mand post-re­im­burse­ment, for ex­am­ple. Go­ing for­ward, al­lo­ca­tion of sup­ply to Chi­na could be­come a com­plex strate­gic de­ci­sion that con­sid­ers the sig­nif­i­cant up­side in vol­ume, but will al­so, in some cas­es, need to be weighed against the low­er price point of drugs re­quired to se­cure na­tion­al re­im­burse­ment in Chi­na. The ques­tion of ramp­ing up lo­cal man­u­fac­tur­ing to sup­ply the lo­cal mar­ket will be square­ly on the ta­ble.

Count on the tal­ent mar­ket to heat up: The rapid growth of the mar­ket is cre­at­ing an ex­cep­tion­al en­vi­ron­ment for tal­ent­ed ex­ec­u­tives at both multi­na­tion­al phar­ma and lo­cal Chi­nese biotech com­pa­nies to pur­sue a range of at­trac­tive ca­reer op­por­tu­ni­ties. To stay com­pet­i­tive in this new mar­ket for tal­ent, com­pa­nies will need to fun­da­men­tal­ly re­think their val­ue propo­si­tion to the tal­ent they hope to hire—and re­tain in Chi­na. Just adapt­ing a glob­al recipe for tal­ent man­age­ment may not be enough to sus­tain dif­fer­en­ti­a­tion.

Plan for “fast and slow” in­te­gra­tion with glob­al R&D: In­te­gra­tion with glob­al R&D re­mains a work-in-progress. The strate­gic in­tent is rel­a­tive­ly clear. But the abil­i­ty to ex­e­cute the strat­e­gy re­mains a chal­lenge in the con­text of what is still a de­vel­op­ing in­no­va­tion ecosys­tem. Suc­cess will de­pend on sev­er­al key fac­tors, in­clud­ing: 1) How much a com­pa­ny can mo­ti­vate and mo­bi­lize its glob­al prod­uct lead­ers to ful­ly en­gage the Chi­na team; 2) Clear strate­gic align­ment and ef­fec­tive com­mu­ni­ca­tion be­tween the glob­al and Chi­na prod­uct teams to dri­ve ro­bust strat­e­gy, along with high qual­i­ty and rapid ex­e­cu­tion; 3) A strong and ca­pa­ble Chi­na team that can put Chi­na in­to the glob­al con­text and ef­fec­tive­ly in­flu­ence the glob­al or­ga­ni­za­tion. This is not an easy for­mu­la to fol­low.

Con­sid­er Chi­na a “must-have” on a se­nior ex­ec­u­tive re­sume with glob­al as­pi­ra­tions: Chi­na ex­pe­ri­ence can be a big ca­reer boost and it’s a mes­sage that will be in­creas­ing­ly heard by mid­dle man­age­ment. What bet­ter prov­ing ground for fu­ture se­nior ex­ec­u­tives than ex­pe­ri­ence run­ning their Chi­na busi­ness? Chi­na is a large, volatile mar­ket, where the com­plex­i­ty of en­gage­ment with ex­ter­nal stake­hold­ers is among the high­est any­where, and the pace of ex­ter­nal change is of­ten greater than the pace of in­ter­nal change. We al­ready have ex­am­ples of this trend, in­clud­ing the cur­rent CEOs of Lil­ly, GSK, and Bio­gen Idec who all held se­nior re­spon­si­bil­i­ties in Chi­na at some point in their ca­reer.

Ex­pect the un­ex­pect­ed: Chi­na will not fail to sur­prise us. While the news cov­er­age has been large­ly pos­i­tive for multi­na­tion­als in the last few years—Chi­na’s new “4+7” vol­ume-based pur­chas­ing pol­i­cy aside—some bumps on the road should be ex­pect­ed. Re­silience and com­mit­ment will be test­ed. Ul­ti­mate­ly, Chi­na re­mains a “high risk, high re­ward” mar­ket.

Chi­na is the most ex­cit­ing health­care sto­ry in the world to­day. The lat­est chap­ter of ro­bust per­for­mance by multi­na­tion­als is just an ex­am­ple of that.

If you en­joyed this blog, please share com­ments and con­sid­er read­ing my pri­or en­tries, all avail­able un­der my LinkedIn pro­file. Most re­cent ones in­clude views on re­cent in­vest­ment trends in Chi­na health­care, re­flec­tions on the Cam­bri­an ex­plo­sion of Chi­na biotechs, and per­spec­tives on 8 rea­sons why Chi­na is the most ex­cit­ing health­care sto­ry in the world right now.


Al­so pub­lished on LinkedIn. Franck Le Deu (@fle864) is a Se­nior Part­ner with McK­in­sey & Com­pa­ny, lead­ing the Health­care Prac­tice in Greater Chi­na and serv­ing clients across Asia. 

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks after winning EU approval to start marketing dapagliflozin as Forxiga, AstraZeneca has racked up another OK for a triplet combo involving the SGLT2 diabetes drug. Named Qtrilmet, the pill combines Forxiga with the DPP-4 inhibitor Onglyza (saxagliptin) and the bedrock drug metformin in a modified-release format. That 3-in-1 approach proved superior in reducing average blood glucose levels to a number of other dual combinations across 5 Phase III trials, including Forxiga plus metformin, Onglyza with metformin, or glimepiride with metformin.

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is custom, an EMA panel on Friday issued its weekly recommendations on marketing applications submitted by drug developers. This week, the agency backed the use of five new therapies — including two Novartis drugs — but issued no negative reviews.

Novartis’ S1P drug for relapsing forms of multiple sclerosis (MS) drug, Mayzent (known chemically as siponimod), which was approved by the FDA in March — has been given the nod by the EMA. The Swiss drugmaker already sells its other MS drug, Gilenya, in both regions.

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures to back those missions.

X-37 uses Atomwise’s AI platform to identify drug targets and – unlike the parent company, which largely sticks to computers  – bring those into a wet lab and preclinical testing.  In addition to AI professionals, it’s led in by part by drug developers from Velocity Pharmaceutical Development.

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

→ Abbott Laboratories has named a successor to CEO Miles White after he announced that he was stepping down in March after 21 years of service. Robert Ford, the company’s COO and president, will take the helm. Ford is known for his work in the $25 billion merger between St. Jude Medical into Abbott in January 2017. White will remain with the company as executive chairman of the board. 

→ After snapping up Novartis’ Swiss facility, Novartis Center of Excellence, in July, Lonza has announced that their CEO, Marc Funk, is hitting the exit for “personal reasons.” Funk has been the CEO of the company for less than a year — brought onto the company back in March. In the meantime, chairman Albert Baehny will serve as interim CEO. 

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

A month after posting positive top-line data from their first Phase III trial of the IL-17A/17F inhibitor bimekizumab, Belgium’s UCB says they’ve added more upbeat results from their second late-stage test in moderate-to-severe plaque psoriasis.

That leaves the company on track for regulatory submissions in the middle of next year, says CMO Iris Loew-Friedrich.
Their drug beat out a placebo on the co-primaries — a 90% improvement in PASI 90 (the Psoriasis Area and Severity Index) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at week 16, compared to placebo. Investigators also boasted of hitting some key secondaries.
UCB is angling to enter an increasingly crowded market space.
In their first of 3 Phase III studies for bimekizumab, researchers touted top-line wins on statistically significant results on clearing plaque psoriasis, including a victory over J&J’s IL-23 contender Stelara on key endpoints. The drug targets both IL-17A and IL-17F, a modification on the IL-17A strategy laid out for Taltz (Eli Lilly) and Cosentyx (Novartis). And the new group also includes J&J’s Tremfya and AbbVie’s Skyrizi.

Social image: UCB